INT48692

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1994
Last Reported 2010
Negated 12
Speculated 6
Reported most in Body
Documents 345
Total Number 351
Disease Relevance 210.30
Pain Relevance 21.31

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (VEGFA) growth (VEGFA) extracellular region (VEGFA)
proteinaceous extracellular matrix (VEGFA) cytoplasm (VEGFA)
Anatomy Link Frequency
endothelial cells 27
blood vessels 7
plasma 7
basement membrane 4
muscle tissues 3
VEGFA (Homo sapiens)
Pain Link Frequency Relevance Heat
Inflammation 1597 100.00 Very High Very High Very High
rheumatoid arthritis 610 100.00 Very High Very High Very High
antagonist 338 100.00 Very High Very High Very High
Glutamate receptor 20 100.00 Very High Very High Very High
endometriosis 11 100.00 Very High Very High Very High
fibrosis 106 99.92 Very High Very High Very High
Bioavailability 30 99.92 Very High Very High Very High
ischemia 327 99.76 Very High Very High Very High
spinal inflammation 63 99.36 Very High Very High Very High
cytokine 894 99.00 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cancer 8818 100.00 Very High Very High Very High
INFLAMMATION 1829 100.00 Very High Very High Very High
Hypoxia 1572 100.00 Very High Very High Very High
Metastasis 1237 100.00 Very High Very High Very High
Rheumatoid Arthritis 721 100.00 Very High Very High Very High
Adhesions 265 100.00 Very High Very High Very High
Hepatocellular Cancer 108 100.00 Very High Very High Very High
Tumor Necrosis Factor Receptor-associated Periodic Syndrome 103 100.00 Very High Very High Very High
Cervical Cancer 41 100.00 Very High Very High Very High
Endometriosis (extended) 24 100.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Pegaptanib is a pegylated aptamer that consists of a RNA oligonucleotide ligand that binds human VEGF 165 with high affinity and specificity.
VEGF Binding (binds) of
1) Confidence 0.48 Published 2007 Journal Indian Journal of Ophthalmology Section Body Doc Link PMC2635972 Disease Relevance 0.36 Pain Relevance 0
Binding affinity with VEGF was measured by using the human VEGF ELISA kit (DY293B; R&D, Minneapolis, MN) for detecting free human VEGF in mixtures of KH902 (concentration ranging from 0.1 pM to 0.5 nM) with human VEGF.
VEGF Binding (affinity) of
2) Confidence 0.47 Published 2008 Journal Molecular Vision Section Body Doc Link PMC2267739 Disease Relevance 0.26 Pain Relevance 0
Furthermore, VEGF/VEGFR interactions can stimulate proliferation, migration, and survival of leukemia/lymphoma cells by autocrine and paracrine loops.
VEGF Binding (interactions) of associated with leukemia and lymphatic system cancer
3) Confidence 0.47 Published 2010 Journal Journal of Oncology Section Body Doc Link PMC2875768 Disease Relevance 1.14 Pain Relevance 0
Thus the lack of VEGFxxxb binding may be particularly significant in this context.
VEGF Binding (binding) of
4) Confidence 0.47 Published 2010 Journal American Journal of Physiology - Lung Cellular and Molecular Physiology Section Body Doc Link PMC2886605 Disease Relevance 0.46 Pain Relevance 0.03
Bevacizumab (Avastin®; Genentech, South San Francisco, CA, USA) is a monoclonal antibody that binds all isomers of vascular endothelial growth factor (VEGF).
vascular endothelial growth factor Binding (binds) of
5) Confidence 0.47 Published 2007 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2701127 Disease Relevance 0.49 Pain Relevance 0.03
Pegaptanib binds to the heparin-binding domain, accounting for its specificity for VEGF165, with an extremely high affinity (Kd = 50 pM) (Lee et al 2005) and inhibits the interaction of VEGF165 with its type-1 and type-2 receptors.
VEGF Binding (binds) of
6) Confidence 0.47 Published 2006 Journal International Journal of Nanomedicine Section Body Doc Link PMC2426796 Disease Relevance 0.61 Pain Relevance 0
6
Compared to pegaptanib which is a modified 28-base ribonucleic acid aptamer that selectively binds VEGF165, bevacizumab is a humanized monoclonal antibody that inhibits all active isoforms of VEGF. 
VEGF Binding (binds) of
7) Confidence 0.47 Published 2007 Journal Indian Journal of Ophthalmology Section Body Doc Link PMC2635996 Disease Relevance 1.06 Pain Relevance 0
Further, VEGF/VEGFR interactions can stimulate proliferation, migration and survival of leukemia/lymphoma cells by autocrinous and paracrinous loops.
VEGF Binding (interactions) of associated with leukemia and lymphatic system cancer
8) Confidence 0.46 Published 2010 Journal J Angiogenes Res Section Body Doc Link PMC2902424 Disease Relevance 0.92 Pain Relevance 0.06
Vascular endothelial growth factor (VEGF) has been recognized as one important contributor (Kvanta et al 1996) in the complex and incompletely elucidated mechanisms of CNV development.


Vascular endothelial growth factor Binding (recognized) of associated with age-related macular degeneration
9) Confidence 0.46 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2699647 Disease Relevance 1.67 Pain Relevance 0.14
Vascular endothelial growth factor (VEGF) has been recognized as one important contributor (Kvanta et al 1996) in the complex and incompletely elucidated mechanisms of CNV development.


VEGF Binding (recognized) of associated with age-related macular degeneration
10) Confidence 0.46 Published 2006 Journal Clinical Interventions in Aging Section Body Doc Link PMC2699647 Disease Relevance 1.64 Pain Relevance 0.14
Counter to prevailing wisdom, simulated increase in production of sVEGFR1 did not lead to significant reduction in intramuscular VEGF-VEGFR2 complex formation.
VEGF-VEGFR2 Binding (formation) of
11) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Given the in vitro evidence that the soluble and full-length VEGFR1's have similar affinities to VEGF [95], we assumed in our model a Kd of 33 pM for VEGF-sVEGFR1 binding, same as that previously used [54] for VEGF-VEGFR1 binding.
VEGF-VEGFR1 Binding (binding) of
12) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
Our simulations also predicted inconsequential effects from incorporating the newly purported binding interaction between NRP1 and VEGF121.
VEGF121 Binding (interaction) of
13) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0 Pain Relevance 0
We have previously developed several computational models of the in vivo biochemical interactions between VEGF121, VEGF165, VEGFR1, VEGFR2, NRP1, and the interstitial matrix in skeletal muscle, including: a spatially-averaged single-tissue model of the human vastus lateralis muscle at rest [54]; and several 3D models for predicting spatial molecular gradients and intra-muscular pro-angiogenic treatment outcomes in resting and exercising rat extensor digitorum longus muscle [55]–[58].
VEGF121 Binding (interactions) of in extensor digitorum longus
14) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.30 Pain Relevance 0
Hence we identified the need for a computational model that predicts the systemic distributions and molecular interactions of VEGF and sVEGFR1 across the human body, to serve as a platform for the mechanistic study of sVEGFR1's purported anti-angiogenic properties, as well as the pre-clinical study of sVEGFR1 as a disease marker and therapeutic agent.


VEGF Binding (interactions) of in body associated with disease
15) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.60 Pain Relevance 0
We propose that the experimental quantification of all major in vivo binding partners for both VEGF and sVEGFR1 from peripheral blood samples to be essential in reconciling the apparent contradiction between predicted and measured VEGF-sVEGFR1 complexed fractions.
VEGF Binding (binding) of in blood
16) Confidence 0.46 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2663039 Disease Relevance 0.06 Pain Relevance 0
However, it does not bind to other biologically active VEGF-A isoforms such as VEGF110, VEGF113, and VEGF121.
VEGF121 Neg (not) Binding (bind) of
17) Confidence 0.44 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698673 Disease Relevance 0.65 Pain Relevance 0.04
It consists of approximately 93% human and 7% murine sequences.82 The antibody itself contains a human IgG1 framework region and the antigen–binding complementarity-determining regions of a murine antibody that binds to VEGF, Mab A.4.6.1.
VEGF Binding (binds) of
18) Confidence 0.43 Published 2010 Journal OncoTargets and therapy Section Body Doc Link PMC2895775 Disease Relevance 0.27 Pain Relevance 0
Comparison of gene signatures from primary tumor, regional, and distant metastasis indicates that VEGF is only overexpressed in distant metastasis and is associated with poor survival.
VEGF Binding (associated) of associated with cancer and metastasis
19) Confidence 0.42 Published 2010 Journal Clinical Medicine Insights. Oncology Section Body Doc Link PMC2883240 Disease Relevance 1.32 Pain Relevance 0
associated with VEGF and fibroblast growth factor with correlation coefficients of 0.58 to 0.78.


VEGF Binding (associated) of in fibroblast
20) Confidence 0.42 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2776981 Disease Relevance 0.77 Pain Relevance 0.08

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox